Reviewing Vivos Therapeutics (NASDAQ:VVOS) and Nemaura Medical (NASDAQ:NMRD)

Vivos Therapeutics (NASDAQ:VVOS) and Nemaura Medical (NASDAQ:NMRD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Earnings & Valuation

This table compares Vivos Therapeutics and Nemaura Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$13.80 million	0.75	-$13.58 million	($10.93)	-0.28
Nemaura Medical	$3,017.00	401.25	-$14.14 million	($0.39)	-0.08

Vivos Therapeutics has higher revenue and earnings than Nemaura Medical. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vivos Therapeutics and Nemaura Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-85.90%	-652.32%	-98.95%
Nemaura Medical	N/A	N/A	-142.69%

Volatility & Risk

Vivos Therapeutics has a beta of 7.74, suggesting that its share price is 674% more volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Vivos Therapeutics and Nemaura Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	0	0	1	0	3.00
Nemaura Medical	0	0	0	0	N/A

Vivos Therapeutics currently has a consensus price target of $6.60, indicating a potential upside of 117.11%. Given Vivos Therapeutics’ higher possible upside, research analysts plainly believe Vivos Therapeutics is more favorable than Nemaura Medical.

Institutional & Insider Ownership

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are owned by institutional investors. 9.6% of Vivos Therapeutics shares are owned by insiders. Comparatively, 40.4% of Nemaura Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Vivos Therapeutics beats Nemaura Medical on 7 of the 13 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.